A threshold cost-effectiveness comparison of infliximab and etanercept in adults with rheumatoid arthritis in the UK.

被引：0
|
作者：
Bansback, N
Brennan, A
Conway, P
Reynolds, AV
机构：
[1] Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[2] Wyeth, Maidenhead, Berks, England
来源：
ARTHRITIS AND RHEUMATISM | 2002年 / 46卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S582 / S582
页数：1
相关论文
共 50 条
  • [21] Etanercept versus infliximab plus methotrexate in rheumatoid arthritis: A cost-effectiveness analysis from the Italian NHS perspective
    Lopatriello, S
    Berto, P
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 725 - 725
  • [22] Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
    M. Cárdenas
    S. de la Fuente
    P. Font
    M. C. Castro-Villegas
    M. Romero-Gómez
    D. Ruiz-Vílchez
    J. Calvo-Gutiérez
    A. Escudero-Contreras
    M. A. Casado
    J. R. Del Prado
    E. Collantes-Estévez
    [J]. Rheumatology International, 2016, 36 : 231 - 241
  • [23] Cost-effectiveness of two TNF inhibitors, etanercept and infliximab, in patients with rheumatoid arthritis in daily clinical practice in the Netherlands
    Creemers, MC
    Kievit, W
    Flendrie, M
    Van den Hoogen, FH
    De Jong, AJ
    Van Riel, PL
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 430 - 430
  • [24] Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
    Cardenas, M.
    de la Fuente, S.
    Font, P.
    Castro-Villegas, M. C.
    Romero-Gomez, M.
    Ruiz-Vilchez, D.
    Calvo-Gutierez, J.
    Escudero-Contreras, A.
    Casado, M. A.
    Del Prado, J. R.
    Collantes-Estevez, E.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2016, 36 (02) : 231 - 241
  • [25] Cost-effectiveness of 102-weeks of infliximab for rheumatoid arthritis.
    Wong, JB
    Breedveld, FC
    Smolen, JS
    Kavanaugh, AF
    van Riel, PL
    Hazes, JMW
    Wong, CJ
    Feagan, BG
    van der Heijde, DM
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S311 - S311
  • [26] Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
    Wong, JB
    Singh, G
    Kavanaugh, A
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S144 - S144
  • [27] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    [J]. PharmacoEconomics, 2014, 32 : 775 - 787
  • [28] COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK
    Emery, P.
    Taylor, P.
    Isaacs, J. D.
    Drost, P.
    Dupont, D.
    Beresniak, A.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A439 - A439
  • [29] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    [J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [30] A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
    Mark J. C. Nuijten
    Peter Engelfriet
    Klaas Duijn
    George Bruijn
    David Wierz
    Marc Koopmanschap
    [J]. PharmacoEconomics, 2001, 19 : 1051 - 1064
12345